Email This Release
Forbius Completes Phase 1 Oncology Dose-Escalation with AVID200, First-in-Class TGF-beta 1 & 3 Inhibitor: Well Tolerated, Target Inhibition Demonstrated at All Dose Levels, Data Reported at SITC
*
marks required fields
Recipient Name:
*
Recipient Email:
Message:
*
Enter security words:
Get Business Wire News on Your Website
Terms of Use
|
© 2024 Business Wire